Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux-E Foam, 0.05%, of Mylan Pharmaceuticals Inc. According to IQVIATM sales data for the 12 month period ending July 2019, the Olux-E Foam, 0.05% market achieved annual sales of approximately $11.1 million. Glenmark’s current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio